Gavin M Bendle

Summary

Affiliation: The Netherlands Cancer Institute
Country: The Netherlands

Publications

  1. ncbi Preclinical development of T cell receptor gene therapy
    Gavin M Bendle
    Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Curr Opin Immunol 21:209-14. 2009
  2. ncbi Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy
    Gavin M Bendle
    Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Nat Med 16:565-70, 1p following 570. 2010
  3. ncbi Requirements for effective antitumor responses of TCR transduced T cells
    Moniek A de Witte
    Division of Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, The Netherlands
    J Immunol 181:5128-36. 2008
  4. ncbi T-cell receptor gene therapy: critical parameters for clinical success
    Carsten Linnemann
    Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Invest Dermatol 131:1806-16. 2011
  5. ncbi TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation
    Moniek A de Witte
    Division of Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, The Netherlands
    J Immunol 181:2563-71. 2008

Collaborators

  • Ton N M Schumacher
  • Todd D Schell
  • Nadine Pouw
  • Moniek A de Witte
  • Carsten Linnemann
  • Marly D van den Boom
  • Harm Van Tinteren
  • John B A G Haanen
  • Maarten Dokter
  • Miriam Coccoris
  • Annelies Jorritsma
  • Elly M Mesman
  • Ji Ying Song
  • Ji-Ying Song
  • Andrew Kaiser
  • Satvir S Tevethia

Detail Information

Publications5

  1. ncbi Preclinical development of T cell receptor gene therapy
    Gavin M Bendle
    Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Curr Opin Immunol 21:209-14. 2009
    ..Here we discuss in which areas preclinical studies in mouse models can or cannot be expected to be of value to guide clinical trial design, and how the available data from preclinical studies should influence forthcoming clinical trials...
  2. ncbi Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy
    Gavin M Bendle
    Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Nat Med 16:565-70, 1p following 570. 2010
    ..Furthermore, we demonstrate that adjustments in the design of gene therapy vectors and target T cell populations can be used to reduce the risk of TCR gene therapy-induced autoimmune pathology...
  3. ncbi Requirements for effective antitumor responses of TCR transduced T cells
    Moniek A de Witte
    Division of Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, The Netherlands
    J Immunol 181:5128-36. 2008
    ..The strategies outlined in this study should be of value to enhance the antitumor activity of TCR-modified T cells in clinical trials...
  4. ncbi T-cell receptor gene therapy: critical parameters for clinical success
    Carsten Linnemann
    Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Invest Dermatol 131:1806-16. 2011
    ..This review highlights those strategies that can be followed to develop TCR gene therapy into a clinically relevant treatment option for cancer patients...
  5. ncbi TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation
    Moniek A de Witte
    Division of Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, The Netherlands
    J Immunol 181:2563-71. 2008
    ..These results demonstrate the value of TCR gene transfer to target otherwise nonimmunogenic tumor-associated self-Ags provided that adoptive transfer occurs under conditions that allow in vivo expansion of the TCR-modified T cells...